Search hospitals > Virginia > Norfolk
Virginia Oncology Associates
Claim this profileNorfolk, Virginia 23502
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
228 reported clinical trials
9 medical researchers
Summary
Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Lung Cancer
Global LeaderStage III
Stage IV
Stage I
Top PIs
Michael A. DansoVirginia Oncology Associates2 years of reported clinical research
Expert in Breast Cancer
Studies Tumors
14 reported clinical trials
24 drugs studied
Michael McCollumVirginia Oncology Associates3 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
8 reported clinical trials
15 drugs studied
Paul Conkling, MDVirginia Oncology Associates4 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
4 reported clinical trials
10 drugs studied
Mark Fleming, MDVirginia Oncology Associates .3 years of reported clinical research
Studies Prostate Cancer
4 reported clinical trials
7 drugs studied
Clinical Trials running at Virginia Oncology Associates
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Pancreatic Cancer
Follicular Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
ALK Gene Rearrangement
Colorectal Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Giredestrant + Phesgo
for Breast Cancer
This trial is testing whether a combination of two drugs is more effective than one drug for patients with advanced breast cancer. The drugs work by blocking signals that help cancer cells grow. The study focuses on patients whose cancer cannot be cured with surgery or other local treatments.
Recruiting2 awards Phase 311 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Virginia Oncology Associates?
Virginia Oncology Associates is a medical facility located in Norfolk, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Virginia Oncology Associates is involved with conducting 228 clinical trials across 127 conditions. There are 9 research doctors associated with this hospital, such as Michael A. Danso, Michael McCollum, Paul Conkling, MD, and Mark Fleming, MD.